ZEAL’s PR on Survodutide phase-2 data presented at ADA: https://www.globenewswire.com/news-release/2023/06/23/2693928/0/en/Data-shows-nearly-19-weight-loss-in-people-with-overweight-or-obesity-in-Boehringer-Ingelheim-and-Zealand-Pharma-Phase-II-trial-with-survodutide-BI-456906.html